SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.
Epistemonikos ID: a8c0efe4d8d76db631d05cbbcfd84b23f045a471
First added on: May 14, 2024